Compare SONY & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SONY | VRTX |
|---|---|---|
| Founded | 1946 | 1989 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | EDP Services |
| Sector | Consumer Staples | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 127.6B | 123.4B |
| IPO Year | 1996 | 2006 |
| Metric | SONY | VRTX |
|---|---|---|
| Price | $24.21 | $547.81 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 29 |
| Target Price | $22.00 | ★ $539.69 |
| AVG Volume (30 Days) | ★ 5.5M | 1.3M |
| Earning Date | 05-13-2026 | 05-04-2026 |
| Dividend Yield | ★ 5.33% | N/A |
| EPS Growth | N/A | ★ 836.54 |
| EPS | N/A | ★ 8.33 |
| Revenue | N/A | ★ $2,488,652,000.00 |
| Revenue This Year | N/A | $10.79 |
| Revenue Next Year | $3.08 | $10.47 |
| P/E Ratio | ★ N/A | $65.79 |
| Revenue Growth | N/A | ★ 46.20 |
| 52 Week Low | $19.32 | $374.17 |
| 52 Week High | $30.34 | $555.32 |
| Indicator | SONY | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 64.70 | 64.11 |
| Support Level | $20.64 | $458.05 |
| Resistance Level | $24.67 | N/A |
| Average True Range (ATR) | 0.30 | 14.06 |
| MACD | -0.01 | 3.82 |
| Stochastic Oscillator | 78.19 | 83.09 |
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is the global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with five major business segments.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.